Several peptide therapeutics are used as replacement therapies in order to supplement peptide hormones when endogenous levels are inadequate or absent. Insulin and adrenocorticotrophic hormone (ACTH) are peptides isolated from natural sources, whereas oxytocin and vasopressin are synthetic peptides.
The global Peptide
Therapeutics Market is estimated to account for US$ 23,319.3 Mn in terms of
value and is expected to reach US$ 57,166.5 Mn by the end of 2027.
Global Peptide Therapeutics
Market: Drivers
Increasing adoption of peptide
therapeutics is expected to aid in growth of the global peptide therapeutics
market over the forecast period. Peptides therapeutics are typically associated
with lower production complexity compared with
protein-based-biopharmaceuticals. This in turn results in lower production
costs, which increases adoption of peptides therapeutics compared to small molecules
and biopharmaceuticals.
Global Peptide Therapeutics Market:
Opportunities
Development of multifunctional
peptides and conjugates is expected to offer lucrative growth opportunities for
players in the market. For instance, in February 2019, researchers from
University of Milan reported that the polypeptide lunasin derived from bioactive
food offered hypocholesterolemic, antioxidant, and anti-inflammatory properties
and can be effective in prevention of cardiovascular disease.
Global Peptide Therapeutics
Market: Restraints
Therapeutic peptides have low
membrane permeability and are prone to hydrolysis and oxidation, which is
expected to hinder growth of the market.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1837
Key Takeaways:
The branded sub segment in the
product type segment in global peptide therapeutics market was valued at US$
12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 at a CAGR
of 9.1% during the forecast period.
Branded medications in the
peptide therapeutics market have extensive patent protections and preferred by
the physicians in developed as well as emerging economies. Moreover, branded
medications are costly as compared to generic peptide therapeutics.
The cancer sub segment in
applications segment held dominant position in the global peptide therapeutics
market in 2018, accounting for 34.3% share in terms of value, followed by
metabolic disorders and central nervous system disorders, respectively.
Increasing prevalence of cancer
is expected to create lucrative opportunities for growth of manufacturers in
the market. For instance, according to the National Cancer Institute, 2016, the
number of new cancer cases per year is expected to increase to 23.6 million by
2030, worldwide.
The parenteral sub segment in
route of administration segment held dominant position in the global peptide
therapeutics market in 20148, accounting for 70.4% share in terms of value,
followed by transdermal route and mucosal route, respectively.
Vast number of parenteral peptide
therapeutics have been launched in the market. These drugs are effective as the
drug is directly administered in the blood stream bypassing gastrointestinal
tract.
Market Trends
The market is witnessing
increasing adoption of peptide therapeutics for the treatment of cancer. For
instance, in January 2020, IBicycle Therapeutics plc., a biotechnology that
develops therapeutics based on its proprietary bicyclic peptide technology,
collaborated with Cancer Research UK for funding in R&D of BT7401, a
multivalent Bicycle CD137 agonist for the treatment of cancer.
Major players in the market are
focused on collaborating with universities for R&D of new peptide
therapeutics. For instance, in 2018, Sapience Therapeutics, Inc., a
biotechnology company focused on R&D in peptide therapeutics, collaborated
with the University of Bath to discover new therapeutic agents.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837
Regulations
Europe
The medicines regulatory
authorities of the Member States, or 'national competent authorities', are
responsible for the authorisation of medicines available in the EU that do not
pass though the centralised procedure.
For clinical trials, European
Medicines Agency maintains only EUDRACT and EUDRAVigilance database. The
National agency of each country is responsible for conducting the trial.
CHMP or Committee for Medicinal
Products for Human use assess the product for marketing approval in EU
In EU, biologic is wide umbrella
term that includes peptides
Non-clinical studies are carried
out according to ICH-S6 guidelines
There is a centralised MAA
procedure; however, biologics are also approved at member state level
Global Peptide Therapeutics
Market: Competitive Landscape
Major players operating in the
global peptide therapeutics market include, AstraZeneca plc., Bachem Holding
AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck &
Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical
Industries Ltd.
Global Peptide Therapeutics
Market: Key Developments
January 2020: Cybrexa Therapeutics,
a privately-held biotechnology company focused on development of
next-generation tumor-targeted cancer therapies, announced CBX-12 (alphalex
exatecan) as the new lead development program. The Cybrexa alphalex technology
platform consists of a pHLIP peptide, linker, and small molecule anti-cancer
agent.
January 2020: Protagonist
Therapeutics, Inc. announced the achievement of a research milestone under its
worldwide license and research collaboration agreement with Janssen Biotech,
Inc., for co-development and commercialization of PTG-200, an oral,
gut-restricted IL-23 receptor antagonist and second generation peptides for the
treatment of inflammatory bowel disease.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1837
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment